Compare ED & CNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ED | CNC |
|---|---|---|
| Founded | 1884 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.3B | 33.5B |
| IPO Year | 2009 | 2001 |
| Metric | ED | CNC |
|---|---|---|
| Price | $107.71 | $65.63 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 16 |
| Target Price | ★ $107.00 | $46.75 |
| AVG Volume (30 Days) | 1.8M | ★ 3.9M |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | ★ 7.63 | N/A |
| EPS | 2.54 | ★ 5.30 |
| Revenue | $16,918,000,000.00 | ★ $194,777,000,000.00 |
| Revenue This Year | $9.18 | $8.31 |
| Revenue Next Year | $4.49 | $1.05 |
| P/E Ratio | $41.87 | ★ $12.27 |
| Revenue Growth | 10.89 | ★ 19.44 |
| 52 Week Low | $94.96 | $28.24 |
| 52 Week High | $116.23 | $69.36 |
| Indicator | ED | CNC |
|---|---|---|
| Relative Strength Index (RSI) | 43.99 | 51.67 |
| Support Level | $106.41 | $63.20 |
| Resistance Level | $114.82 | $68.39 |
| Average True Range (ATR) | 1.84 | 2.32 |
| MACD | -0.10 | -0.07 |
| Stochastic Oscillator | 39.63 | 45.02 |
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York, including New York City, and small parts of New Jersey. The two utilities generate nearly all of Con Ed's earnings following the sale of its clean energy business to RWE in early 2023.
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 20 million medical members as of December 2025, mostly in Medicaid (about 64% of membership), the individual exchanges (about 28%), and Medicare (about 5%). The company also provides Medicare Part D pharmaceutical plans.